Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Company Overview

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Key Stats

• Today's Range: $7.90 to $13.50
• 50-Day Range: $2.81 to $15.10
• 52-Week Range: $2.73 to $23.80
• Volume: 36.12 million shs
• Average Volume: 812,372 shs
• Market Capitalization: $42.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Galmed Pharmaceuticals Stock Analysis - MarketRank™

Galmed Pharmaceuticals scored higher than 22% of companies evaluated by MarketBeat, and ranked 901st out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Galmed Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Galmed Pharmaceuticals is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galmed Pharmaceuticals is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Galmed Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.56% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently increased by 235.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galmed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Galmed Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.56% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently increased by 235.54%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.36

News Sentiment

Galmed Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

25 people have searched for GLMD on MarketBeat in the last 30 days. This is an increase of 2,400% compared to the previous 30 days.

MarketBeat Follows

12 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLMD Stock Analysis - Frequently Asked Questions

How have GLMD shares performed this year?

Galmed Pharmaceuticals' stock was trading at $5.46 at the start of the year. Since then, GLMD stock has increased by 84.8% and is now trading at $10.09.
View the best growth stocks for 2024 here.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($13.08) EPS for the quarter, beating the consensus estimate of ($18.00) by $4.92.

When did Galmed Pharmaceuticals' stock split?

Shares of Galmed Pharmaceuticals reverse split on the morning of Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL) and Ocular Therapeutix (OCUL).

Company Calendar

• Last Earnings: 6/01/2023
• Today: 9/19/2024
• Next Earnings (Estimated): 11/27/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLMD
• CUSIP: N/A
• CIK: 1595353
• Web: www.galmedpharma.com
• Phone: (723) 693-8448
• Fax: 972-3693-8447
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,910,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.06%
• Return on Assets: -23.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.48
• Quick Ratio: 6.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $33.02 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 5,045,000
• Free Float: 4,046,000
• Market Cap: $34.81 million
• Optionable: Not Optionable
• Beta: 0.67